UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000012926 |
|---|---|
| Receipt number | R000014977 |
| Scientific Title | Effect of androgen deprivation therapy on bladder cancer recurrence. |
| Date of disclosure of the study information | 2014/01/23 |
| Last modified on | 2014/01/23 02:50:13 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Effect of androgen deprivation therapy on bladder cancer recurrence.
Acronym
Effect of androgen deprivation therapy on bladder cancer recurrence.
Scientific Title
Effect of androgen deprivation therapy on bladder cancer recurrence.
Scientific Title:Acronym
Effect of androgen deprivation therapy on bladder cancer recurrence.
Region
| Japan |
Condition
Condition
Bladder cancer and prostate cancer
Classification by specialty
| Urology | Adult |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
Investigate effect of androgen deprivation therapy on bladder cancer recurrence.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Recurrence free survival
Cumulative recurrence
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 50 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male
Key inclusion criteria
Patients with double primary cancer of bladder and prostate cancer.
Key exclusion criteria
Bladder cancer except for urothelial cancer.
Target sample size
200
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Hiroji Uemura |
Organization
Yokohama City University Hospital
Division name
Urology
Zip code
Address
3-9 Fukuura, Kanazawaku, Yokohama, Japan
TEL
045-787-2800
hu0428@med.yokohama-cu.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Hiroji Uemura |
Organization
Yokohama City University Hospital
Division name
Urology
Zip code
Address
3-9 Fukuura, Kanazawaku, Yokohama, Japan
TEL
045-787-2800
Homepage URL
hu0428@med.yokohama-cu.ac.jp
Sponsor or person
Institute
Yokohama Cancer of Prostate Group
Institute
Department
Personal name
Funding Source
Organization
Grant
Organization
Division
Category of Funding Organization
Non profit foundation
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2014 | Year | 01 | Month | 23 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2014 | Year | 01 | Month | 10 | Day |
Date of IRB
Anticipated trial start date
| 2014 | Year | 01 | Month | 10 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Clinicopathological features of bladder and prostate cancer.
RFS and cumulative recurrence.
Expressions of AR and its related molecules in clinical samples.
Management information
Registered date
| 2014 | Year | 01 | Month | 23 | Day |
Last modified on
| 2014 | Year | 01 | Month | 23 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014977
